Latest Safety News

Syntara Limited has initiated dosing in its Phase 1c SATELLITE trial for a novel topical treatment targeting keloid scars, marking a significant step in addressing a $3.5 billion global market. The study, led by Professor Fiona Wood, will evaluate safety and early efficacy over three months.

Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.

X2M Connect Limited has launched a $4.9 million capital raising through a Placement and Entitlement Offer to reduce debt and accelerate expansion in IoT, AI, and renewable energy markets.

St Barbara Limited reported a robust Q4 June 2025 with gold sales surging 34% and full-year production meeting guidance, supported by a strong cash position and improved safety metrics.

Orcoda Limited has locked in six new multi-year SaaS contracts with Australian community transport providers following a successful government-backed trial, pushing its annual recurring revenue to approximately $5 million.

Matsa Resources has officially commenced mining operations at its Devon Pit Gold Mine, with ore haulage to begin late July and first processing slated for mid-September 2025.

Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.

HITIQ Limited is set to debut its PROTEQT concussion management system in the UK on August 4, 2025, uniquely integrating with NHS 111 telehealth services to offer free medical guidance. This launch marks HITIQ’s first international consumer market entry and a strategic step in its global expansion.

Castile Resources has integrated bismuth as a by-product into its Rover 1 Bankable Feasibility Study following China’s export restrictions, positioning itself as a key supplier amid global supply shocks. The company also advances exploration with innovative technology and secures strategic partnerships in critical mineral supply chains.

Australian Strategic Materials Limited (ASM) reminds eligible shareholders that its underwritten Share Purchase Plan closes on 17 July 2025, offering shares at a 20% discount. The plan is underwritten to $3 million by Canaccord Genuity, aiming to bolster ASM’s capital base.

Spacetalk Ltd has raised $3 million through convertible notes from its largest shareholder and converted $1 million of secured debt, positioning the company for international growth and new product development.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.